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restudy. In control group, no anti-hyperlipidemic drug was administered. One
PTCA region of intereat par patient was spaeified at registration and was
analysed in a core laboratory by quantitative Coronaryangiography (QCA).
Restenosis was defined as a recurrent Iuminal stenosis of more than 50%
in the dilated segment at the time of restudy. Seventy eight patients (40
for Probucol and 38 for control) completed the study and restenosie rate in
Probucol group was Significantly IOWerthan in COfWOl group (23% vs 57%,
p < 0.01). Subjects were divided into =- 2.7 mm (n= 41) and s 2.7 mm (n
= 37) subgroups acmrding to reference diamater. The results of QCA were
shown in the table.
Reference vessel s 2.7 mm > 2,7mm
(mm) Probucol control Probucol control
Acute geln 0.99+ 0.32 0.97 + 0.37 n.e. 1.30 + 0.47 t.16 + 0.63 n,s,
Late10-S 0.20 + 0.43 0.78 + 0.57 p <0.01 0.54+ 0.67 0.46+ 0.63 n.e.
Net gain 0.79 + 0.46 0.19 + 0.55 p <0.01 0.75+ 0.91 0.69+ 0.54 n.s.
In patients with a reference vessel >2.7 mm, restenoeie rate was 217. in
Probucol group and 45Y0in COntrOlgroup (n.s.). However in thes 2.7 mm
subgroup, restenosis rate in Probueol group was 24%, significantly lower
than in Controlgroup, 75% (p < 0.01).
/n conclusion, Probucol administered for 4 weeks prior to PTCA was
effaetivein preventing restenosis after PTCA in corona~ arteriess 2.7 mm.
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CLAPT ia a multicenter, prospective, randomized trial to assess the effect
of a 2-year treatment with Iovastatin on restanosis after PTCA and non-
dilated coronary sagrnents (=-20% degree stenosis). Loveetatin was atarted
4 weeks prior to PTCA. Main inclusion criteria were cholesterol 200-300
mg/dl, triglycerides -=250 mg/dl, age 18 to 70 yeara and the presence of at
least 1 additional coronary lesion > ’20% beside the stenosis scheduled for
PTCA. Main exclusion criteria were unstable angina, coronary arlery bypasa
grafts and previous PTCA. During 1991 to 1994, 228 male patienta were
randomized 4 weeka prior to PTCA to usual care [UC] (diet; n = 114; age
53.7; BMI 26.4 kdmz) or special care [SC] (diet plus Iovastetin; n = 112;
age 54.1; BMI 25.9 kg/m2). Lovaetatin was titrated during follow-up visits
to attain a serum LDL-cholesterol < 120 mddl. Total- (SC/UC: 242/248
mgfdl) and LDL-cholesterol (SC/UC: 17S/179 m@dl)decreased by 21% and
27% in the Iovastatin treatad group and by 5% and 5% in the usual Care
patienta after 4 months. Quantitative coronaty angiography wea performed
at baseline (PTCA) and repeated after 4 and 24 months. Analysis of the
baseline and follow-up Coronaw arIeriograms waa carried out byquantitetive
eomputar analysis on blinded cinefilms. 92% and 71% of the patients had a
4-month and 24-month coronav angiogram, reepeetively. Prfmaty endpoint
was the change of the mean segment diameter of non-dilated segments
averaged per patient. One secondary endpoint was to compare the change
of the minimal lesion diameters averaged par patient between dilated and
non-dilatadsegments. The detailed results will be presentad.
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Tranilast,an anti-allergicdrug, preventsrestenosisafter PTCA(TREAT
study).We estimatedthe effactiveneasof tranilaston preventingresteno-
sis afterdirectionalcoronaryatheractomy(DCA)accordingto vesselsize.
Aftertheprocedure,39 patients(60Ie$ions,trenilastgroup)weretreatadby
oraltreniiastfor 3 months,and 143patienta(178lesions,controlgroup)did
not receivedit. Accordingto referencevesaelsize,the Iesioneweredivided
intotwoaubgroups;>3 mm group (30 lesions each in either group) and -=3
mm group (89Ieeionain trenilastgroupand87 lesionsin thecontrolgroup).
Therewas no differencein baseline charaeteristiea between the trenilast
and control group, clinically and angiogrephically. The initial and 3-month
follow-up angiograms were examined in both groups. Angiographic analyses
were performed with QCA, and restenosis was defined as > 50’% atenosis
at 3-month follow-up. Results are as follows:
Subgroup Tranilaat(n = 60) Control (n= 176) p value
3-monthatenoaia < 3mm 30& 25 43 k 24
(%)
p <0.05
z 3mm 27& 16 36& 22 p <0.01
3-monthMLD <3 mm 1.79 + 0.73 1.51 + 0.69
(mm)
p = 0.06
23 mm 2.39 h 0.57 1,99 * 0.70 p <0.01
reatanoaiarate < 3mm 20,0 31,5 n.a.
(“/6) 23 mm 3,3 20,7 p <0.05
Conclusion: Tranilast improves both 3-month stenosis and 3-month MLD
after DCA in < 3 mm group as well as in z 3 mm group. Furthermore its
prevents restenosis at 3-month follow-up more strongly in z 3 mm group.
Tranilast after DCA is encouraging therapy for corona~ artery dieease.
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Paclitexel (Texol@)is a new microtubule stabilizing drug with potent antitumor
activity. It influences the eytoskeleton equilibrium by increasing the aasembly
of stable microtubules and thereby intereets with many cellular functions.
The aim of this study was to evaluate the potential of paclitexel to prevent
restenosis in vivo. After induction of a defined plaque formation in the dght
carotid afterfee of 66 New Zealand rabbite by elaetrieel stimulation, 27 ani-
mala underwent balloon dilatation and subsequent local paclitaxel delivety of
10 ml paclitexel (10 ~mol/L) with the double balloon. 29 animals sewed as
control with angioplasty only and 10 animals were eolely eleetrostimulated.
Vessels were excised 1, 4 and 8 weeks following intervention. lmmunohis-
tologieel staining with antibodies against bromodeoxyuridine, alpha-aetin,
macrophages, von Willebrandt factor and tubulin wae performed. Electron
microscopy served for the detection of cytoskeletd changes.
Ffesu/ts.’Corresponding to a strong decrease in earfy intimal proliferation
the intimal area in paclitexel treated animals increaead only minimally during
the obaetvation period from 0.179 mmz (1 weak) to 0.193 mmz (8 weeks). In
control animals the intimal area increaeedconsiderably to O.301mmz8weeks
after intervention. Marked vessel enlargement compared to control animals
could be obeerved at any time point (Luminal area 8 weeks after intervention:
paclitaxel group: 0.754 mmz, control: 0.417 mmz). Tubulin staining revealed
changes in microtubule assembly which were atrictly limited to the intimal
area.
Conclusion: Local peclitexel delive~ proved safe and effective in this
animal model both by reduction of neointima formation and enlargement in
veeeel size. Thus, the application of the highly Iipophilic paclitaxel via the
double balloon may be a promising approach for local therapy of restenosis.
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VLA-4 blockade has been shown to favorably reduce neointimal prolif-
eration in experimental modele of transplant mronaty arteriopathy. The
tranaendothelial trafficking of inflammato~ cells is similar following arle-
rial injury with balloon angioplasty. We hypothesized that blocking VLA-4
and endothelial cell interaction would limit naointimal proliferation following
arterial injury in the rabbit atherosclerotic model. The femoral arteriea of 20
New Zealand white rebbita underwent induction of focal atherosclerosis us-
ing air desieeetion followed by a 4 week atherogenic diet. Arterial injury was
then performed using a 2 mm angioplasty ballocmat 8 atm for 60 seconds.
Animals were randomized to receive the VIA-4 blocker (1 mg/kg SC) or
placebo 12 hours before arterial injuty and daily for 1 week. Three weeks
following arterial injury, the arteries were hatvested and histologiesdanalysis
was performed. IBDA.l.
